Discussion about this post

User's avatar
Big Pharma Sharma's avatar

Great points throughout this post, especially re: diminishing returns. Can't tell you how many market research projects I or other BioPharma colleagues have reviewed proposals for, where consulting firms have ratcheted up the number of KOL interviews to unnecessary amounts. It's a great mechanism to bloat project costs and often adding little value after a certain point number.

Crazy anecdotes re: PDW. I knew that disease was uniquely challenging, but those patient stories were shocking. The ice cream truck one specifically made me think of the "Clickers" from HBOS' "The Last of Us". Just a terrible disease. Congrats to the Soleno team for getting a new therapeutic over the finish line.

Expand full comment
aharon levy's avatar

Very insightful/useful breakdown as always; thanks.

Expand full comment
5 more comments...

No posts